Acquisition China Chinese Expansion Finance Guangdong Healthcare Hong Kong Investment IPO Medicine Pharmaceutical Revenue Shenzhen stock exchange
Baiyang Medicine, a Chinese A-share listed pharmaceutical company, announced its plan to issue H-shares and list on the main board of the Hong Kong Stock Exchange to enhance its capital strength and global business strategy. This move aligns with the trend of Chinese innovative pharmaceutical companies submitting IPO applications to the Hong Kong Stock Exchange this year, focusing on various medical sectors such as antibody-drug conjugates (ADCs), autoimmune inflammation, GLP-1 metabolic diseases, AI pharmaceuticals, renal disease treatment, and gene therapy. Several A-share pharmaceutical companies have successfully completed dual A+H listings, with more companies progressing towards Hong Kong listings. Established in…
News Timeline:
Track the development of this news story across the Internet.